We built Izana on evidence, not optimism.
Two papers sit underneath this whole product: one clinical, one about the market. Here's the short, honest version of both, with every number sourced.
If the burden is what ends IVF, support the burden.
couples quit IVF before a baby. Not because a cycle failed. Because the months are exhausting.
Shen et al., 2026 ↗a gentler experience roughly halved dropout in a clinical study. Burden can be moved. It's a lever.
Verberg et al., 2008 ↗finishing more cycles lifts the chance of a baby from 51% to 72%. The gap is couples who carry on.
Malizia et al., NEJM 2009 ↗Izana supports the burden, so couples finish.
Two papers. One in clinic, one in market.
The Inter-Cycle Gap
Why IVF care stops at the clinic door, and what a clinically-governed companion can do about it.
- ~37%of couples discontinue IVF before a live birth (62 studies, 330,593 patients).
- ~6 hrsof a two-week cycle is inside the clinic. The rest is lived, unseen, at home.
- 22.5%of male partners screen positive for anxiety: the invisible half of the couple.
- 4design principles: clinically governed, phase-aware, dyadic, closed-loop.
The Cost of Waiting
Why delayed childbearing is driving a structural, decades-long rise in fertility treatment.
- 131of 237 countries are now below the replacement fertility rate.
- 1 in 8Spanish babies are now born through assisted reproduction.
- ~1Massisted-reproduction cycles run in Europe each year, rising annually.
- <1 in 10couples who could benefit in India are currently reached.
Four rules a real companion must follow.
From the clinical paper. Miss any one, and you've rebuilt the problem you set out to fix.
Clinically governed
It works under your clinic's authority. Never around it. It doesn't diagnose, prescribe, or change protocol.
Phase-aware
Stimulation, retrieval, the two-week wait, each is a different experience. Generic content isn't support.
Dyadic
Burden sits in the couple, and the decision to stop is made together. Support that reaches one reaches half.
Closed-loop
Data in, guidance out, and the clinic sees it and shapes it. Open at either end, it fails.
The most trustworthy thing in the paper is what it refuses to claim.
“Izana does not claim to make an embryo implant. The protocol belongs to the clinic; Izana instruments the gap around it.”
We improve the odds a couple finishes the cycles they start. And, through the cumulative arithmetic of live births, the babies that follow from finishing rather than stopping. Nothing more. Nothing less.
We don't ask you to believe it. We ask you to measure it.
The clinical paper closes with a deliberately low-risk pilot, designed to be run against your own baseline.
One small cohort.
Beginning treatment at your clinic, alongside entirely standard care.
One window.
Long enough to span a stimulation cycle and the interval that follows.
No cost, no protocol change.
The medicine stays exactly as it is. Izana runs in parallel, in the gap.
Your own numbers.
Continuation, burden and partner engagement, measured against your prior results.
Every number, sourced.
Key references behind the claims on this site. Full citation lists are in the downloadable papers.
Shen et al. (2026). Worldwide prevalence of discontinuation in fertility treatment. Int. J. Gynecology & Obstetrics.
Verberg et al. (2008). Why do couples drop out from IVF treatment? Human Reproduction.
Malizia, Hacker & Penzias (2009). Cumulative live-birth rates after IVF. NEJM.
Domar et al. (2010). Why insured US patients drop out of IVF. Fertility & Sterility.
Walker et al. (2023). The effects of male anxiety and depression on IVF outcomes. Human Reproduction.
Lyzwinski, Elgendi & Menon (2024). Wearable reproductive-health tracking: systematic review. JMIR.
Boivin, Griffiths & Venetis (2011). Emotional distress and ART failure: meta-analysis. BMJ.
United Nations (2024). World Population Prospects. 131/237 countries below replacement.
Evidence first. Always.
It's how we earn a place beside your clinic, and your trust.